Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07892300) titled 'Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer' on Oct. 17.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
Primary Sponsor: Oliver Jonas
Condition:
Lung Cancer
Mesothelioma
Suspected Lung Cancer
Suspected Mesothelioma
Intervention:
Drug: Implantable Micro- drug delivery Microdevice (IMD)
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: October 30, 2026
Target Sample Size: 20
To know more, visit https://clinicaltrials.gov/study...